More Noxopharm Ltd. news
Noxopharm Ltd.ASX: NOX

First COVID-19 Patient Treated in Veyonda Study

Oct 1, 2020 at 10:49 PM EDT · Issued by Noxopharm Ltd.

Filed with ASX · Oct 1, 2020 at 10:49 PM EDT

On 6ix: 6ix.com/news/first-covid-19-patient-treated-in-veyonda-study

Noxopharm Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Noxopharm Ltd. on 6ix

Story so far

  • Veyonda COVID-19 Study Approved For Immediate StartSep 1, 2020
  • Peer-Reviewed Publication Strengthens Case For VeyondaAug 11, 2020
  • FDA allows Veyonda Pre-IND Submission for COVID-19May 19, 2020

Earlier from Noxopharm

  • Veyonda COVID-19 Study Approved For Immediate StartAug 31, 2020
  • Appendix 4E and Audited Financial Statements FY2020Aug 30, 2020
  • Peer-Reviewed Publication Strengthens Case For VeyondaAug 10, 2020
  • Noxopharm 2020 June quarter Appendix 4C & Activities ReportJul 28, 2020
  • Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’Jul 23, 2020

Later from Noxopharm

  • Noxopharm Loan Terms Amended to Benefit CompanyOct 5, 2020
  • Noxopharm Quarterly Activities Report & Appendix 4COct 14, 2020
  • Dedicated Septic Shock Company EstablishedNov 5, 2020
  • Veyonda To Be Tested In Combination With Opdivo In TrialNov 8, 2020
  • Independent Discovery Validates DARRT Cancer TherapyNov 12, 2020
All Noxopharm news releases↗

Follow Noxopharm into a list and get an email when it puts out news.

Follow Noxopharm
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer